Linezolid was compared to vancomycin for the treatment of ventilator-associated<unk> , and showed cost-effectiveness as an alternative to vancomycin treatment as it had a higher cure rate and prices per treatment were similar.  One study reported that oropharingeal decontamination decreased the incidence of ventilator-associated<unk>  from 4% to less than 1% in the studied population. The cost of the intervention was less than $2500.
Pneumonia cost-effectiveness of therapy
Bacterial pneumonia cost-effectiveness of therapy
Hospital-acquired pneumonia cost-effectiveness of therapy
Tuberculosis cost-effectiveness of therapy
Pneumoconiosis cost-effectiveness of therapy
Acute respiratory distress syndrome cost-effectiveness of therapy
Influenza cost-effectiveness of therapy
Multi-drug-resistant tuberculosis cost-effectiveness of therapy